BioCentury | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

...from Velo Bio LLC (Morrisville, N.C.) and Glenveigh Medical LLC (Chattanooga, Tenn.). Mark Zipkin ATryn (rhAT) DIF, Digibind, DigiFab...
BioCentury | Jun 9, 2017
Clinical News

Velo begins Phase IIb/III for digoxin immune fab to treat severe preeclampsia

...Morrisville, N.C.) began a double-blind, U.S. Phase IIb/IIIa trial to evaluate digoxin immune fab (DIF, DigiFab...
...Chattanooga, Tenn. Velo Bio LLC , Morrisville, N.C. Product: Digoxin immune fab ( DIF , DigiFab...
...treatment Status: Phase IIb/IIIa started Milestone: Submit NDA (2019) Julian Zhu AMAG Pharmaceuticals Inc. Glenveigh Medical LLC Velo Bio LLC Digoxin DIF DigiFab Digoxin...
BioCentury | Apr 2, 2012
Company News

BTG sales and marketing update

...BTG launched DigiFab in the U.K. to treat digoxin toxicity or overdose. BTG gained the polyclonal...
BioCentury | Dec 19, 2011
Company News

Paladin sales and marketing update

...Paladin launched DigiFab in Canada to treat digoxin toxicity or overdose. Health Canada approved the polyclonal...
...Details were not disclosed (see BioCentury, Feb. 7). Paladin has exclusive Canadian commercialization rights to DigiFab...
...company of BTG plc (LSE:BGC, London, U.K.), under a 2010 deal. BTG gained rights to DigiFab...
BioCentury | Feb 7, 2011
Clinical News

DigiFab regulatory update

...BTG's marketing partner Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) said Health Canada approved DigiFab to treat...
...BTG to market DigiFab in Canada (see BioCentury, March 8, 2010). BTG gained rights to DigiFab...
...acquisition of Protherics plc (see BioCentury, Dec. 15, 2008). BTG plc (LSE:BGC), London, U.K. Product: DigiFab...
BioCentury | Dec 6, 2010
Strategy

BTG's parallel worlds

...$250.6 million) in stock. That deal gave BTG two marketed acute care products, CroFab and DigiFab...
...until Oct. 1, 2010. CroFab is a polyclonal antibody against North American rattlesnake venom, and DigiFab...
BioCentury | Sep 6, 2010
Company News

BTG, Nycomed sales and marketing update

...U.S. marketing rights from Nycomed to CroFab , a polyclonal antibody against rattlesnake venom, and DigiFab...
...30. BTG expects to pay Nycomed about $14.5 million. BTG has rights to CroFab and DigiFab...
...worldwide revenue of £24.2 million ($36.6 million) and £5.4 million ($8.2 million) of CroFab and DigiFab...
BioCentury | Mar 8, 2010
Company News

BTG, Paladin sales and marketing update

...Paladin received exclusive rights from BTG's Protherics Inc. subsidiary to market DigiFab in Canada. The polyclonal...
BioCentury | Feb 8, 2010
Clinical News

DigiFab regulatory update

...Swissmedic approved DigiFab to treat digoxin toxicity. The polyclonal antibody against digoxin (digitalis) glycosides is also...
...in the U.K. and Canada. Beacon Pharmaceuticals Ltd. (Tunbridge Wells, U.K.) has rights to market DigiFab...
...to begin marketing DigiFab in the U.S. in October. BTG plc (LSE:BGC), London, U.K. Product: DigiFab...
BioCentury | Dec 15, 2008
Analyst Picks & Changes

Analyst picks & changes

...to CroFab and DigiFab to BTG. CroFab is a North American pit viper antivenom, and DigiFab...
Items per page:
1 - 10 of 36